First Trust NYSE Arca Biotechnology Index Fund


First Trust NYSE Arca Biotechnology Index Fund

  • Price (USD)125.22
  • Today's Change-0.21 / -0.17%
  • Shares traded39.21k
  • 1 Year change38.46%
Data delayed at least 15 minutes, as of Oct 21 2017 01:00 BST.
More ▼

Profile and investment

Fund typeOpen Ended Investment Company
Investment style (stocks)Market Cap: Mid
Investment Style: Growth
Morningstar categoryHealth
Launch date19 Jun 2006
Price currencyUSD
DomicileUnited States
Manager & start date
Roger Testin
19 Jun 2006
Daniel Lindquist
19 Jun 2006
Jon Erickson
19 Jun 2006
David McGarel
19 Jun 2006
Stan Ueland
08 Nov 2006
Chris Peterson
18 Mar 2016
Pricing frequencyDaily
Total net assets
1.15bn USD
As of Sep 30 2017
Net expense ratio0.56%
Front end load--
Deferred load--
Redemption fee--
Min. initial investment--
Min. additional investment--
Initial IRA--
Additional IRA--
Available for saleMexico, United States
More ▼

Top 5 holdings

Top 5 holdings as a per cent of portfolio
Category average% Net assets% Short% Long
Company1 year changePortfolio weightLong allocation
Kite Pharma Inc--5.28%
Juno Therapeutics Inc
Alnylam Pharmaceuticals Inc
Neurocrine Biosciences Inc
ACADIA Pharmaceuticals Inc
Per cent of portfolio in top 5 holdings: 22.81%
Top 10 Holdings


Asset type

Asset type

US stock96.56%
Non-US stock3.38%
US bond0.00%
Non-US bond0.00%

Top 5 sectors

Fixed income

Top 5 regions

United States96.56%
Sector and region weightings are calculated using only long position holdings of the portfolio.
Intra-day ETF pricing data provided by
© Thomson Reuters Click for restrictions
The performance data shown in tables and graphs on this page is calculated in USD of the fund/index/average (as applicable), on a Bid To Bid / Nav to Nav basis, with gross dividends re-invested on ex-dividend date. Past performance is not necessarily a guide to future performance; unit prices may fall as well as rise.
All managed funds data located on is subject to the FT Terms & Conditions
All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
All data shown on this page, unless noted otherwise is Data Source and Copyright: Morningstar, Inc. 2017
All Rights reserved
© 2017 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.
Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.